Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye

Study Purpose

Primary Objective.

  • - To assess the proportion of patients with Sjögren's dry eye who demonstrate impaired corneal sensitivity.
Secondary Objectives.
  • - To assess corneal sensitivity via Cochet-Bonnet esthesiometer.
  • - To assess tear secretion via Schirmer I test.
  • - To assess OPAS questionnaire results.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Patient must be ≥18 years of age at time of screening. 2. Patient must have had a confirmed diagnosis of Sjögren's for a minimum of 3 months before enrollment, as determined by either serologic antibody testing (anti-SSA/anti-SSB) or biopsy of minor salivary glands. 3. Patient must have had a confirmed diagnosis of dry eye for a minimum of 3 months before enrollment, as determined by signs and/or symptom assessment. 4. Fluorescein corneal staining with a cobalt blue light must show punctate corneal fluorescein staining or staining consistent with corneal epithelial damage equivalent or greater than 1 on the NEI scale by dry eye at enrollment. 5. Only patients who satisfy all informed consent requirements may be included in the study. The patient and/or his/her legal representative must read, sign, and date the IRB-approved informed consent document before any study-related procedures are performed. 6. Patients must have the ability and willingness to comply with study procedures.

Exclusion Criteria:

1. Inability to speak and understand English sufficiently to understand the nature of the study, provide written informed consent, and allow the completion of all study assessments. 2. Presence of active ocular infection (bacterial, viral, protozoal) in either eye, as deemed by the Investigator or confirmed culture. 3. Previous use of OXERVATE® ophthalmic solution. 4. Presence of gross epithelial defect, including a defect with stromal involvement. 5. Any concurrent medical condition that, in the judgment of the Investigator, might interfere with the conduct of the study or confound the interpretation of the study results. 6. Any eyelid abnormalities, such as lagophthalmos, entropion, ectropion, or other neuromuscular abnormalities, that result in prolonged exposure of the corneal surface. 7. Concurrent epithelial corneal disease or dystrophy unrelated to dry eye, such as anterior basement membrane dystrophy. 8. Inability to remove contact lenses for a minimum of 3 hours before corneal sensitivity testing. 9. Inability to discontinue use of all topical ophthalmic treatments for a minimum of 3 hours before corneal sensitivity testing. 10. Inability to suspend use of any neurostimulatory drugs or devices (including but not limited to nasal varenicline, iTear100, etc.) for treating dry eye or increasing tear film for 6 hours before testing. 11. Ocular surgery (including but not limited to laser-assisted in situ keratomileusis, photorefractive keratectomy, tube shunt/trabeculectomy, or cataract surgery) within the last 6 months. 12. History of corneal stromal surgery, including anterior lamellar keratoplasty, deep anterior lamellar keratoplasty, and penetrating keratoplasty. 13. Current participation in another clinical study that may affect corneal sensitivity or tear production.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06411132
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Dompé Farmaceutici S.p.A
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Scott Hauswirth, OD
Principal Investigator Affiliation Dompé Farmaceutici SpA
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Sjögren Syndrome, Dry Eye
Additional Details

This clinical study has been designed to evaluate the proportion of patients with confirmed Sjögren's dry eye who present with neurosensory abnormalities via demonstration of increased ocular pain and/or a decrease in corneal sensitivity. A multicenter design allows for a greater diversity of patient population with Sjögren's dry eye. The number of sites allows for quick enrollment and expedited results that will help physicians understand the corneal sensitivity levels in the population of patients with Sjögren's dry eye. This study design is minimally invasive and may be completed in a single visit provided all qualification criteria are met. This design reduces the time commitment from patients, thereby reducing barriers for enrollment and participation.

Arms & Interventions

Arms

: Full Analysis set

The full analysis set includes all patients who meet all the inclusion criteria and none of the exclusion criteria at the end of the screening procedure. All the analyses on the primary and secondary endpoints will be provided on this population. The screened population consists of all patients who sign the ICF and are assigned a patient identification number. Please note that the sample size may vary depending on feasibility.

Interventions

Other: - observational study

observational study

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

West Coast Eye Institute, Bakersfield, California

Status

Recruiting

Address

West Coast Eye Institute

Bakersfield, California, 11901

Site Contact

Sandeep Walia, MD

[email protected]

+39 02 583831

University of Colorado, Aurora, Colorado

Status

Recruiting

Address

University of Colorado

Aurora, Colorado, 80045

Site Contact

Kaleb Abbott, OD

[email protected]

+39 02 583831

Bowden Eye, Jacksonville, Florida

Status

Recruiting

Address

Bowden Eye

Jacksonville, Florida, 32256

Site Contact

Jerry Robben, OD

[email protected]

+39 02 583831

University of Miami, Miami, Florida

Status

Recruiting

Address

University of Miami

Miami, Florida, 33136

Site Contact

Alfonso Sabater, MD

[email protected]

+39 02 583831

Tufts University School of Medicine, Boston, Massachusetts

Status

Recruiting

Address

Tufts University School of Medicine

Boston, Massachusetts, 02111

Site Contact

Pedram Hamrah, MD

[email protected]

+39 02 583831

Minnesota Eye Consultants, Woodbury, Minnesota

Status

Recruiting

Address

Minnesota Eye Consultants

Woodbury, Minnesota, 55125

Site Contact

Mark Buboltz, OD

[email protected]

+39 02 583831

Eye Associates of North Jersey, Dover, New Jersey

Status

Recruiting

Address

Eye Associates of North Jersey

Dover, New Jersey, 07801

Site Contact

Eric Mann, MD

[email protected]

+39 02 583831

Weil Cornell Medicine, New York, New York

Status

Recruiting

Address

Weil Cornell Medicine

New York, New York, 10021

Site Contact

Christopher Starr, MD

[email protected]

+39 02 583831

Triangle Eye Consultants, Raleigh, North Carolina

Status

Recruiting

Address

Triangle Eye Consultants

Raleigh, North Carolina, 27617

Site Contact

Preeya Gupta, MD

[email protected]

+39 02 583831

Vita Eye Clinic, Shelby, North Carolina

Status

Recruiting

Address

Vita Eye Clinic

Shelby, North Carolina, 28150

Site Contact

Patrick Vollmer, OD

[email protected]

+39 02 583831

Focus Eye Care, Wilmington, North Carolina

Status

Recruiting

Address

Focus Eye Care

Wilmington, North Carolina, 28405

Site Contact

Crystal Brimer, OD

[email protected]

+39 02 583831

University of Pennsylvania, Philadelphia, Pennsylvania

Status

Recruiting

Address

University of Pennsylvania

Philadelphia, Pennsylvania, 19104

Site Contact

Mina Massaro, MD

[email protected]

+39 02 583831

Toyos Clinic, Nashville, Tennessee

Status

Recruiting

Address

Toyos Clinic

Nashville, Tennessee, 37215

Site Contact

Melissa Toyos, MD

[email protected]

+39 02 583831

Periman Eye Institute, Seattle, Washington

Status

Recruiting

Address

Periman Eye Institute

Seattle, Washington, 98119

Site Contact

Laura Periman, MD

[email protected]

+39 02 583831